Novo Nordisk registers Phase 3 obesity trial for zenagamtide; MTC safety study enrolling
Novo Nordisk posted a new Phase 3 obesity study for oral zenagamtide and is enrolling patients by invitation in a real-world study of thyroid cancer risk tied to GLP-1 medicines.
Two Novo Nordisk studies were posted or updated this week, one testing a new oral obesity drug and one examining a long-standing safety question for the GLP-1 class.
- Zenagamtide, an oral tablet for excess body weight, is being tested in a Phase 3 trial called "AMAZE 9" that is not yet recruiting, with an estimated enrollment of 950 participants1. The primary outcome is relative change in body weight from baseline at week 0 to week 761.
- Novo Nordisk is running a database linkage study using real-world data to determine whether GLP-1 receptor agonist medicines for type 2 diabetes and weight management are linked to an increased risk of medullary thyroid carcinoma2. The study is enrolling by invitation and will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC2, with an estimated enrollment of 93,600,000 participants drawn from claims data.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.